Wednesday, October 27, 2010 9:08:55 AM
(June 30, 2010)
TSX - Symbol : DNG
Common shares outstanding : 30,214,285
Options : 3,000,000 (average price $0.31)
Convertible note : 6,466,035 ($0.40)
Fully diluted shares : 39,680,320
Share price : $0.37 (June 30, 2010)
Market value (fully diluted) : $14.7 million CDN
Institutional shareholders ( over 70%)
Recent DYN News
- Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/02/2024 08:10:00 PM
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Dyne Therapeutics Announces CEO Transition • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days • GlobeNewswire Inc. • 03/13/2024 11:30:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 09:36:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 09:35:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 09:35:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:53:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 01:19:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 01:18:51 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 01:16:36 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/05/2024 01:22:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 12:41:52 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2024 12:40:50 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 12:35:27 PM
- Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:37:54 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 02:33:01 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:08:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 12:49:10 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2024 10:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:27:23 PM
- Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference • GlobeNewswire Inc. • 02/14/2024 09:15:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM